LONDON, March 28 Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
Critics ask if Tillerson can turn from corporate to national interest
WASHINGTON, Dec 11 The central question facing Exxon Mobile Corp. chief executive Rex Tillerson if he becomes U.S. secretary of state is whether a life-long oil man with close ties to Russia can pivot from advancing corporate interests to serving the national interest.
REFILE-UPDATE 4-Trump likely to name Exxon CEO secretary of state -source
BALTIMORE, Dec 10 U.S. President-elect Donald Trump is expected to name the chief executive of Exxon Mobil Corp as the country's top diplomat, a source familiar with the situation said on Saturday, an appointment that would put in place an official with close ties to the Russian government.